M&A Deal Summary |
|
|---|---|
| Date | 2020-09-01 |
| Target | NAMSA |
| Sector | Medical Products |
| Buyer(s) |
ArchiMed
Omnes Capital |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
Try For Free 7-Day Free Trial
ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €5 to €300 million per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 26 |
| Sector (Medical Products) | 5 of 8 |
| Type (Buyout (LBO, MBO, MBI)) | 11 of 15 |
| State (Ohio) | 1 of 1 |
| Country (United States) | 3 of 5 |
| Year (2020) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-18 |
ActiGraph
Pensacola, Florida, United States ActiGraph is a developer of wearable, remote monitoring technology for academic studies, and drug trials. ActiGraph’s mobility and sleep tracking hardware, software and analysis solutions are the most widely used research-grade monitoring systems for activity in the world. ActiGraph was founded in 2004 and is based in Pensacola, Florida. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-12 |
Zyto
Dusseldorf, Germany Zyto is a fully integrated developer, manufacturer and distributor of technologically advanced cancer diagnostics tests and equipment for hospitals, clinics and private medical practices. Zyto’s three operating companies – Zytomed, ZytoVision and 42 Life Sciences – provide doctors with the diagnostic tools they need to understand the genetic changes that occur (or don’t occur) in individual patients’ tumors. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2004 |
| PE ASSETS | 5.7B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Omnes Capital formerly known as Credit Agricole Private Equity (CAPE) is the investment arm of financial services group Credit Agricole. Omnes Capital looks to invest in a range of investment stages and transaction types, including LBO/expansion, venture capital, mezzanine, renewable energy, co-investment, infrastructure, and special situations. The Firm's LBO/expansion group looks to invest €25 to €80 million to support growth initiatives and buyouts of small and mid-cap businesses operating in a variety of industries. Omnes Capital generally invests in businesses operating in France and Italy. Omnes Capital's mezzanine area was formed in 2002 and looks to provide €5 to €30 million of junior capital to similar sized established businesses. In addition to Omnes Capital's traditional equity and subordinated debt investment arm, the Firm also invests in infrastructure projects as well as provides capital for distressed businesses with €10 to €150 million in revenue. Omnes Capital was formed in 2004 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 155 of 161 |
| Sector (Medical Products) | 4 of 4 |
| Type (Buyout (LBO, MBO, MBI)) | 73 of 73 |
| State (Ohio) | 1 of 1 |
| Country (United States) | 10 of 10 |
| Year (2020) | 6 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-20 |
Biofutur
L'Isle-Adam, France Biofutur is a group of medical biology analysis laboratories, managed by independent medical biologists. The Biofutur group wishes to continue its development thanks, among other things, to the quality of its local medical care and its patient service. Biofutur is based in L'Isle-Adam, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-07 |
Adents High-Tech International
Massy, France Adents High-Tech International engages in design, development, and distribution of traceability solutions. Adents High-Tech International was founded in 2007 and is based in Massy, France. |
Sell | - |
